Predictive Factors for Poor Progression-free Survival in Patients with Non-small Cell Lung Cancer Treated with Nivolumab

Nivolumab has shown promising effects in patients with non-small-cell lung cancer (NSCLC) as a second- or later-line treatment. This study aimed to identify patients who would not experience any benefit from nivolumab treatment. In this study, data for 201 patients treated with nivolumab during 17 D...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Anticancer Research 2017-10, Vol.37 (10), p.5857-5862
Hauptverfasser:	Taniguchi, Yoshihiko, Tamiya, Akihiro, Isa, Syun-Ichi, Nakahama, Kenji, Okishio, Kyoichi, Shiroyama, Takayuki, Suzuki, Hidekazu, Inoue, Takako, Tamiya, Motohiro, Hirashima, Tomonori, Imamura, Fumio, Atagi, Shinji
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Biomarkers, Tumor - blood Carcinoma, Non-Small-Cell Lung - blood Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Non-Small-Cell Lung - surgery Disease-Free Survival Female Humans Japan Kaplan-Meier Estimate L-Lactate Dehydrogenase - blood Lung Neoplasms - blood Lung Neoplasms - drug therapy Lung Neoplasms - mortality Lung Neoplasms - pathology Male Middle Aged Multivariate Analysis Proportional Hazards Models Retrospective Studies Risk Factors Steroids - therapeutic use Time Factors Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!